

References

I-9010

1. Hemlibra prescribing information. Genentech Inc. January 2024.
2. Srivastave A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.
3. National Hemophilia Foundation. Bleeding Disorders A-Z Overview Inhibitors Treatment for Inhibitors. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/treatment-for-inhibitors>.
4. Institute for Clinical and Economic Review. Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value. April 2018.
5. National Hemophilia Foundation. Bleeding Disorders A-Z/ Types/ Hemophilia A. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a>.
6. CDC Centers for Disease Control and Prevention. Inhibitors and Hemophilia. Accessed at: <https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>.
7. National Hemophilia Foundation. One Size Does Not Fit All: Individualized Therapy. Dr Steven Pipe. February 2017. Accessed at: <https://www.hemophilia.org/educational-programs/education/online-education/one-size-does-not-fit-all-individualized-therapy>.
8. National Hemophilia Foundation. Bleeding Disorders A-Z/ Overview/ Inhibitors/ Immune Tolerance. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/immune-tolerance>.
9. Medical and Scientific Advisory Council (MASAC) MASAC Document 268 – Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors. April 2022.
10. Institute for Clinical and Economic Review. Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value. November 2020.

- 11.gov. NCT04023019. Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE). Accessed at: <https://clinicaltrials.gov/ct2/show/NCT04023019?term=NCT04023019&draw=2&rank=1>.
12. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia Volume 25, Issue 4. April 2019.